Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIESENCE for Postoperative Ocular Inflammation and Pain
NCT07832552Phase 3Enrolling by invitation
- Sponsor
- Harrow
- Start
- May 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-operative ocular inflammation and post-operative ocular pain comparing TRIESENCE Treatment Arm with Placebo (Sham) Control Arm (2 arms). Primary endpoints: Proportion of Subjects With No Anterior Chamber Cells (Grade 0) at 14 days and Proportion of Subjects With No Ocular Pain (NPRS = 0) at 8 days. Started May 2026; status: enrolling by invitation.
02
Drugs
triamcinolone
03
Conditions
post-operative ocular inflammationpost-operative ocular pain
Beyond the preview
Go deeper on NCT07832552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832552.